ASLN(Delisted)
ASLAN Pharmaceuticals·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 0
Bearish signal 1
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ASLN
Aslan Pharmaceuticals Limited
A biopharmaceutical company that develops novel therapeutics for cancer and inflammatory diseases
3 Temasek Avenue Level 18 Centennial Tower, Singapore 039190
--
ASLAN Pharmaceuticals Limited was incorporated in the Cayman Islands in June 2014. The company is a biopharmaceutical company focused on clinical-stage immunology, developing innovative therapies to transform patients' lives. The company's product portfolio is led by eblasakimab (also known as ASLAN 004), a potential first-in-class human monoclonal antibody that binds to the IL-13 receptor α1 subunit (IL-13Rα1), blocking the signaling of the two pro-inflammatory cytokines IL-4 and IL-13, which are at the core of triggering atopic dermatitis symptoms such as skin redness and itching.
Company Financials
EPS
ASLN has released its 2023 Q4 earnings. EPS was reported at -0.78, versus the expected -0.78, meeting expectations. The chart below visualizes how ASLN has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
